Navigation

Hepatitis C (children and young people) - peginterferon alfa and ribavirin [ID373]

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

Status: History
Expected date of issue: November 2013
Process: MTA
Topic area:
  • Digestive system
  • Infectious diseases
 

NICE project team

Technical Lead: Richard Diaz
Communications manager: Phil Ranson
Project manager:

Jeremy Powell

Assessment Group / Evidence Review Group:

Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 16 March 2012
Closing date for invited submissions / evidence submission: 1 October 2012
1st appraisal committee meeting: 20 June 2013
2nd appraisal committee meeting: 21 August 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • Roche (peginterferon alfa 2-a, ribavirin)
  • Merck Sharp and Dohme (peginterferon alfa 2-b, ribavirin)

Patient/carer groups

  • British Liver Trust
  • Children’s Liver Disease Foundation
  • Hepatitis C Trust

Professional groups

  • British Society of Gastroenterology
  • Royal College of Nursing
  • Royal College of Paediatrics and Child Health
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government

 

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and
  • Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Possible Comparator manufacturer(s)

  • N/A

Relevant research groups

Assessment team

  • Southampton Health Technology Assessment Centre

Associated Guideline Groups

  • National Collaborating Centre for Women’s and Children’s Health

Associated Public Health Groups

  • To be confirmed

Top


 

Project history

Date Update
27 November 2013 TA300 Hepatitis C (children and young people) - peginterferon alfa and ribavirin published
Top


 

Key documents

This page was last updated: 31 December 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.